Agensys Rounds Up $41M

Santa Monica-based Agensys has raised $41.3M, in a Series D round, the company announced today. Agensys, which is developing therapeutic antibodies targeted at prostate and other cancers, said that the round was co-led by Duquesne Capital Management and JAFCO Co. Other investors in the round included Innovis Investments, Nextech Venture, as well as existing investors Bear Stearns Health Innoventures, Alta Partners, HBM BioVentures, Lombard Odier Darier Hentsch & Cie, H&Q Life Sciences Investments, and Orbimed Associates. Kenan Turnacioglu of Duquesne Capital and Hironori Hozoji of JAFCO have joined the firm's board as part of the funding round. More information »